<DOC>
	<DOCNO>NCT00383591</DOCNO>
	<brief_summary>Persistence anti-HBs antibody Month 24 , 30 36 subject complete primary vaccination evaluate . The anamnestic response booster dose evaluated subject anti-HBs antibody titres &lt; 10 mIU/ml previous timepoint . The study also evaluate effect booster dose vaccine ( Month 42 ) primary vaccination .</brief_summary>
	<brief_title>Comparison Adjuvanted Hepatitis B Vaccine Double Dose Engerix™-B Pre- /Haemodialysis Patients Aged ≥15 Years</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects complete primary vaccination course . A male female &gt; = 15 year age time first vaccination . Written inform consent obtain subject/ parent guardian subject . If subject female , nonchildbearing potential , childbearing potential , abstinent use adequate contraceptive precaution one month prior enrollment two month last vaccination . Use investigational nonregistered drug vaccine study vaccine within 30 day precede booster dose study vaccine , plan use study period . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>